Acute community-acquired respiratory tract infections (RTIs) are common and persistent causes of morbidity, disability, and mortality. RTIs represent ∼60% of all community-acquired bacterial infections [1, 2] and account for two-thirds of all antibiotic prescriptions written for the treatment of community-acquired infections.
globally, with significant mortality [6] . The incidence of CAP is ∼1-3 per 1000 adults per year, of whom 80% are managed in the community, with a mortality rate of 1%-2%. When CAP is sufficiently severe to warrant hospitalization, the associated mortality rate increases to 5%-10% [7] . The disease usually affects patients aged 160 years, many of whom have underlying lung or cardiovascular disease or diabetes, have a history of alcohol abuse, or are immunosuppressed [8] .
Effective empirical treatment is necessary for RTIs. Diagnostic techniques for RTIs are insensitive and slow, and fulminant RTIs may be rapidly fatal without adequate antimicrobial therapy. The treatment must reflect the nature of the RTI, the most prevalent pathogens found in these diseases, and their sensitivity to antibiotics in any particular geographic region. In this context, it is necessary to emphasize that resistant strains of commonly encountered bacteria have developed, and continue to develop, in different locations from which they spread throughout the world. As a result, resistance to commonly used antibiotics is widespread, necessitating specific identification of local antibiotic sensitivity patterns ( figure 1 ) and often the use of new antimicrobial agents that have a broad antimicrobial spectrum suitable for patients in defined geographic settings. A new additional problem stems from the growing number of pathogens that have been shown to cause RTIs (e.g., Haemophilus parainfluenzae and Chlamydophila pneumoniae). Thus, these organisms also require consideration when prescribing antimicrobials empirically for RTIs.
With this growing clinical need, a new antimicrobial drug, moxifloxacin, a novel 8-methoxy quinolone, has been developed. Moxifloxacin exerts potent bactericidal activity against a wide range of pathogens and in addition possesses pharmacokinetic properties that result in high concentrations in the circulation and tissues, thereby providing adequate bactericidal concentrations at the foci of infection [9] [10] [11] . The primary objective in the development of moxifloxacin was to produce an appropriate spectrum antibiotic for the treatment of community-acquired RTIs with a good tolerability profile, good efficacy against the relevant pathogens, and low propensity for the development of bacterial resistance, thus benefiting patients and helping clinicians to treat these diseases.
This review examines the extent to which the properties of moxifloxacin represent an important step toward fulfilling the growing clinical need for more effective antibiotics.
KEY CAUSATIVE PATHOGENS RESPONSIBLE FOR RTI
The major bacterial pathogens isolated in RTIs are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (table 1) [12] .
Acute sinusitis. In acute bacterial sinusitis, the organisms most frequently isolated in samples obtained by sinus aspiration are S. pneumoniae (31%) and H. influenzae (21%). Other pathogens include gram-negative bacteria (9%), anaerobes (6%), Staphylococcus aureus (4%), M. catarrhalis (2%), other streptococci, including Streptococcus pyogenes (2%), and various anaerobic bacteria (6%) found in maxillary sinusitis of dental origin [4] .
Acute exacerbations of chronic bronchitis (AECB). The most frequently isolated pathogens in AECB are H. influenzae (36%), Haemophilus parainfluenzae (27%), M. catarrhalis (12%), S. pneumoniae (11%), and S. aureus (3%) [13] . The ranges found in different studies include H. influenzae (23%-60%), M. catarrhalis (7%-42%), and S. pneumoniae (10%-17%) [5] .
CAP. S. pneumoniae is the most important CAP respiratory pathogen in Europe, being involved in an estimated 1%-36% of community-acquired cases and 7%-76% of hospital-acquired cases [7] . Legionella species are demonstrated in 0%-15% of CAP cases, often in outbreaks associated with ∼15% mortality [14] . Awareness and demonstration of Mycoplasma pneumoniae is increasing to such an extent that rates of 25%-75% in CAP have been noted, the incidence being up to 20 cases per 1000 people per year [15] . The prevalence of C. pneumoniae has also increased, perhaps because of improved methods and increased recognition, and now accounts for 0%-18% of such cases [16] . A recent Canadian report found that 7% of patients with CAP had Legionnaires disease [17] . The incidence of S. aureus is 3% (0%-10%), particularly after influenza virus infection or in injection drug users.
Mechanisms and extent of resistance. From a therapeutic point of view, a new antibiotic for treating RTIs must not only have a wide range of activity against a broad spectrum of gram- positive, gram-negative, and atypical bacterial species, but it must also be capable of overcoming the intrinsic and acquired resistance mechanisms of many of these strains against the antimicrobial agents commonly used to treat RTIs. Antibiotic resistance among respiratory tract pathogens is especially common with antibiotics that have been traditional first-line agents, such as penicillin derivatives, first-generation cephalosporins, tetracycline, or macrolides (e.g., erythromycin). Indeed, many organisms have become resistant to multiple antibiotic classes [18, 19] . Recently, these strains have shown a marked increase globally, with penicillin resistance affecting more than 40% of pneumococcal strains in the United States. Many of these penicillin-resistant S. pneumoniae strains are also resistant to macrolides, lincosamides, trimethoprim-sulfamethoxazole (TMP-SMX), chloramphenicol, and cephalosporins [10] [11] [12] . Similarly, 185% of strains of M. catarrhalis produce b-lactamases, as do 17%-68% of strains of H. influenzae [20] . These b-lactamase-positive strains of H. influenzae may also be resistant to co-amoxiclavulanic acid [21] and show increased MICs to some cephalosporins. Resistance to TMP-SMX has also been found among H. influenzae strains [22] . Moreover, tetracyclines and macrolides lack bactericidal activity against mycoplasmas [23] . The resistance of respiratory tract pathogens to individual antimicrobial agents or to a range of antimicrobials has important therapeutic implications. Community-acquired RTIs require treatment, often empiric, with an antibiotic that has a wide spectrum of activity that has not evoked and is not likely to elicit resistance and that has pharmacokinetic properties that produce concentrations in respiratory tissues sufficient to kill the infecting pathogens. Treatment directed toward resistant pathogens with potent bactericidal drugs may be expected to lead to improved clinical outcomes and overall lower costs, particularly if hospital admissions and respiratory failure can be prevented [24] . The treatment costs of AECB associated with hospitalization [25] and the overwhelming cost burden for CAP in the hospital setting [26] mean that any new therapy that allows more patients to be treated in the outpatient or community settings is likely to generate significant savings, especially for patients aged у65 years.
RATIONALE FOR THE DEVELOPMENT OF MOXIFLOXACIN
A new broad-spectrum antibacterial agent with powerful bactericidal actions is required in order to rapidly resolve the clinical features of the infection. Such rapid resolution of a potentially serious infection will also lessen the need to admit patients from the community into hospital, thereby decreasing both the burden of the illness to individual patients and its cost to society.
In addition, the new agent must be effective against atypical pathogens, which infect up to 40% of patients with CAP and are also resistant to some of these antibiotics [27, 28] , and must have a good safety profile (table 2) . Moreover, an effective new antimicrobial agent is necessary in light of the therapeutic problems posed by the increasing prevalence of antibiotic resistance of the common respiratory tract pathogens, which have become increasingly resistant to traditional first-line antibiotics such as penicillins and macrolides [29] .
Moxifloxacin is an 8-methoxy quinolone, derived originally from nalidixic acid that has undergone first a piperazine substitution at position 7 of the naphthyridine nucleus and then fluorination at position 6. The development of moxifloxacin involved a carbon for nitrogen substitution at position 8, as well as a 7-azabicyclo modification, together with insertion of an 8-methoxy side chain. As a result of these structural modifications, moxifloxacin has significantly improved activity, compared with earlier quinolones, against gram-positive and atypical organisms while maintaining good activity against gram-negative bacteria [9, 11, 30, 31] .
The pharmacokinetic properties, excellent bioavailability, and long half-life of moxifloxacin [32] permit once-daily dosing. In addition to achieving high and sustained circulating concentrations, moxifloxacin is !50% protein bound. Consequently, moxifloxacin has higher values for pharmacodynamic parameters such as peak concentration/MIC or 24-h area under the curve/90% MIC (MIC 90 ) than other fluoroquinolones such as levofloxacin, sparfloxacin, and gatifloxacin (figure 2) [33] . Excellent tissue penetration results in high concentrations of moxifloxacin in the bronchial mucosa, alveolar macrophages, epithelial lining fluid, and sinus mucosa [9, 32] , yielding potent and sustained bactericidal action at the site of the RTI. There is no cytochrome P-450-mediated metabolism of moxifloxacin that contributes to the lack of significant drug interactions with drugs metabolized by this pathway [34] . lower than the concentrations of moxifloxacin found, for example, in the circulation and in pulmonary tissues (table 4) . Similarly, Gehanno et al. [35] showed that moxifloxacin readily penetrates into sinus mucosa, attaining concentrations 200-300 times those of the MICs of the common pathogens that cause acute sinusitis. Moreover, Buxbaum et al. [36] showed that the in vitro activities of moxifloxacin were unaffected by the penicillin susceptibility status of S. pneumoniae strains (0.125 mg/L) but that penicillin-intermediate and penicillin-resistant isolates tended to be less susceptible to older quinolones, such as levofloxacin. Furthermore, the in vitro MICs of moxifloxacin against a range of S. pneumoniae strains are superior to sparfloxacin and grepafloxacin against penicillin-resistant S. pneumoniae [36] . It has also been shown that resistance to macrolides does not affect the activity of moxifloxacin [1] .
MOXIFLOXACIN MICS AGAINST RESPIRATORY TRACT PATHOGENS
Debbia et al. [37] showed that moxifloxacin was also more potent than ciprofloxacin, ofloxacin, sparfloxacin, and pefloxacin against macrolide-resistant S. pyogenes. Moxifloxacin was the most rapidly and extensively bactericidal (99.9% killing in 6 h) of the quinolones tested against macrolide-susceptible and -resistant S. pyogenes. Moxifloxacin was also found to be active against most S. aureus strains [38, 39] .
The MICs confirm that moxifloxacin is highly active in vitro against both the gram-positive and gram-negative organisms commonly implicated in RTIs, such as S. pneumoniae, S. pyogenes, S. aureus, H. influenzae, and M. catarrhalis [40] . This antibacterial activity is not diminished when the organisms are resistant to b-lactams, macrolides, tetracyclines, or TMP-SMX. It has been shown that the overall in vitro activity of moxifloxacin is superior to penicillin, amoxicillin, co-amoxiclavulanic acid, cefuroxime, clarithromycin, and azithromycin for a range of respiratory tract pathogens [41] . Moxifloxacin is also as active, or more active, than comparator quinolones (table 3) [10, 11] .
DEVELOPMENT OF MOXIFLOXACIN RESISTANCE
In vivo and in vitro experiments undertaken with moxifloxacin show a low frequency of mutations resulting in the development of resistance in S. aureus, S. pneumoniae, and H. influenzae [42, 43] . With a 400-mg dose of moxifloxacin, high tissue levels of moxifloxacin are attained rapidly, and these levels exceed the MIC 90 values for respiratory pathogens for a 30-h period. This, together with the bactericidal nature of the drug, induces rapid killing that, combined with low spontaneous mutation rates, results in eradication of the infecting organisms with maintenance of moxifloxacin susceptibility. Evidence suggests that moxifloxacin may have a lower potential than other quinolones to induce bacterial resistance in vitro and in vivo because of its high intrinsic activity against 2 intracellular targets: DNA topoisomerase IV (in gram-positive bacteria) and DNA gyrase (in gram-negative organisms) [44, 45] .
DESIGN OF MOXIFLOXACIN CLINICAL STUDIES
This review summarizes the results of 13 studies of the use of moxifloxacin in the treatment of RTIs. Four of the studies involve patients with acute sinusitis; 5 provide results from the treatment of CAP; and 4 studies report the results of treating AECB with moxifloxacin. The clinical trials, performed in 30 countries between 1997 and 1998 among 2618 patients, were designed to study the effects of treatment with moxifloxacin or a comparator antibiotic on the clinical course of the RTI, as well as the bacteriologic outcome. All studies were designed to isolate and identify the primary infecting pathogens and to define the moxifloxacin MIC 90 values of these organisms to correlate MIC 90 values with clinical and bacteriologic outcomes.
To expedite the isolation and culture of the pathogens, in keeping with the recommendations of societies for clinical microbiology and infectious diseases, primary isolation of the pathogens was carried out in local laboratories under conditions that were optimal to prevent loss of sensitive species such as H. influenzae and S. pneumoniae and to avoid overgrowth by Enterobacteriaceae and Pseudomonas species The identification of isolates to species level was achieved with the API system (bioMérieux). The etiologic role of atypical pathogens (Chlamydophila, Mycoplasma, and Legionella) was established serologically. Urinary antigen tests for Legionella were not done. Of 289 patients yielding pathogens, 42 (15%) were isolated from blood and sputum simultaneously and 32 (76%) of 42 were S. pneumoniae. Thus, 25% of all S. pneumoniae isolated were from blood and sputum. No positive result of blood culture was identified in any patient during or after treatment with moxifloxacin.
All patients with CAP and AECB were asked to provide pretreatment sputum samples that were checked by Gram stain. By use of the Chodosh criteria [46] , when squamous epithelial cells predominated (у25/low-power field), the samples were rejected as saliva. Patients with acute sinusitis had middle meatal swabs taken (31%), or samples were obtained by sinus catheterization (20%), whereas in 49% of the studied patients, isolates were obtained by sinus puncture. Microbiologic invalidity was defined either by failure to culture a likely pathogen or failure to obtain a sputum or sinus sample. In all patients, attempts were made to obtain followup samples. If the patient's condition had improved, invasive methods were not used. Eradication occurred when the causative organism or organisms could not be isolated from the posttreatment sample. Persistence was defined as finding the pretreatment pathogen in the follow-up sample, whereas superinfection was considered to have occurred when a new organism was isolated from follow-up samples. When no followup sample could be obtained for culture, and if the patient was clinically cured, eradication of the causative organism was presumed, whereas failure to respond clinically was considered to reflect presumed persistence of the causative pathogen. When a diagnosis of atypical infection was based on a serological diagnosis, only the clinical outcome was evaluated.
For determination of MICs, the agar dilution and microbroth dilution techniques [47] were considered to have only limited availability. All the laboratories were therefore provided with E strips of moxifloxacin and the comparator drugs [48] . There was excellent correlation between the MIC 90 values determined with the E test and with the agar dilution method. Irrespective of the value of the MIC 90 , the antibiotic regimen was only changed if the clinical response was unfavorable.
RESULTS OF MOXIFLOXACIN CLINICAL STUDIES AND EFFICACY OF MOXIFLOXACIN
Demographic data. The total number of patients treated with moxifloxacin valid for per-protocol analyses was 2618, which included 802 patients with acute sinusitis, 1017 with AECB, and 799 with CAP.
Acute sinusitis. The clinical and bacteriologic outcomes of treatment with moxifloxacin (400 mg once daily for 7 days) for the treatment of acute sinusitis have been compared with cefuroxime axetil-treated patients in 4 multinational trials [49] . A total of 802 patients met the protocol criteria for evaluation of the clinical efficacy of moxifloxacin therapy, with 282 (35%) of 802 of these patients found to be valid for microbiologic assessment of eradication rates of pretreatment bacterial isolates. In the cefuroxime axetil-treated group, 505 patients were valid for clinical evaluation, of whom 200 (40%) were evaluated microbiologically. The bacteriologic and clinical outcomes were assessed 1 week after the end of treatment. In most patients who were cured, no microbiologic samples were available at the end of treatment, so that values for eradication and presumed eradication were combined, as were values for persistence and presumed persistence.
The most commonly encountered pathogens were S. pneumoniae, H. influenzae, M. catarrhalis, and S. aureus. Most of these organisms were eradicated in both the moxifloxacin and cefuroxime axetil treatment groups (table 5). The overall clinical success rate (resolution or improvement) of moxifloxacintreated patients was 96%, a value almost independent of the infecting organism (table 5) . Similarly, the mean eradication rate for all bacterial isolates treated with moxifloxacin was 96%.
The clinical success rate (93%) and bacterial eradication rate (92%) were slightly lower in the cefuroxime axetil-treated patients. These results were similar to those of Siegert et al. [50] , who reported a clinical success rate of 97% with moxifloxacin and of 91% with cefuroxime axetil, and who reported bacteriologic eradication rates of 95% and 84%, respectively. Penicillin-resistant S. pneumoniae strains (MIC, у2 mg/L) were isolated from 6 patients. All of these patients were cured with moxifloxacin treatment.
AECB. The clinical and bacteriologic outcomes of treatment with moxifloxacin (400 mg once daily for 5 days) for the treatment of AECB were compared with the results of 10 days' treatment with clarithromycin [51] . In total, 1017 patients were found to be valid for per-protocol analyses; of these, 477 (47%) were found to be valid for bacteriologic assessment, having had a pathogen isolated before treatment. Of the 785 patients in the clarithromycin treatment group, 338 (43%) were found to be valid for bacteriologic assessment. The bacteriologic and clinical outcomes in both groups 1 week after the end of treatment are shown in table 6. Both clinical and bacteriologic success after moxifloxacin were noted in 95% of patients, with rates 190% for infection with all species other than P. aeruginosa, where high MICs were noted for some strains (12 of 30 had MICs у2 mg/L, of which 4 of 12 showed persistent infection). Overall, the results of treatment with clarithromycin were similar to moxifloxacin (table 6).
The results of the studies confirm that moxifloxacin is effective in the treatment of AECB. Similar results were reported by Wilson et al. [52] , who reported a clinical cure rate of 89% at follow-up (21-28 days posttreatment for moxifloxacin), with a bacteriologic response of 77%, which was significantly superior to the bacteriologic response rate in the clarithromycin group (62%). Chodosh et al. [53] found eradication rates of 94%-100% for moxifloxacin against S. pneumoniae, H. influenzae, H. parainfluenzae, and M. catarrhalis, whereas clarithromycin and cefuroxime axetil cleared only 74% and 81% of H. influenzae, respectively.
CAP. The treatment of CAP with either moxifloxacin (400 mg once daily for 10 days) or a comparator antibiotic (amoxicillin or clarithromycin) has been compared in 5 multinational trials. In total, 799 patients receiving moxifloxacin were found to be valid per protocol; of these, 243 (30%) patients had a bacterial pathogen isolated before starting treatment [54] . A total of 525 of the patients in the comparator groups were found to be valid per protocol, and 174 (33%) of these were found to be valid for microbiologic assessment. Clinical and bacteriologic outcome were evaluated 1 week after the end of treatment.
The most common bacterial pathogens are shown in table 7, with overall clinical success rates of 92% and bacterial eradication rates of 94% for moxifloxacin. The highest bacteriologic success rates were recorded with infection by H. influenzae (100%) and the lowest with K. pneumoniae (83%). The results of treatment with clarithromycin were similar to moxifloxacin, but clinical and bacteriologic success rates were lower with amoxicillin [54] .
The moxifloxacin MIC 90 values were similar to those found in preclinical studies. Nineteen strains of S. pneumoniae had reduced penicillin susceptibility (у0.1 mg/L), 14 of which were also resistant to clarithromycin (18.0 mg/L), as identified before treatment with moxifloxacin. The bacteriologic success rate in the eradication of these resistant organisms was similar to the CAP group as a whole, confirming that moxifloxacin is active against penicillin-and macrolide-resistant organisms. Moxifloxacin was effective and at least as active as clarithromycin in the treatment of CAP [55] , achieving clinical (94.9%) and bacteriologic (94.0%) success at the end of therapy of 190% (table 8) .
Causative pathogens. Pretreatment pathogens were identified in 282 (35%) of 802 patients with acute sinusitis [49] ; in 477 (47%) of 1017 patients with AECB (54); and in 243 (30%) of 799 with CAP [54] .
In the patients treated with moxifloxacin (400 mg once daily), 9 bacterial species accounted for 84% of the causative pathogens (table 9) . The bacteriologic and clinical response rates were excellent, with high bacterial eradication rates (у90%), except for P. aeruginosa (67%). The modal MICs for moxifloxacin are in good agreement with those observed in preclinical studies-for example, 0.125-0.25 mg/L for S. pneumoniae, 0.064-0.125 mg/L for S. aureus, and 0.064 mg/L for H. influenzae [11] .
Overall, S. pneumoniae was cultured in 26% of the RTIs treated with moxifloxacin [56] ; more specifically, it was the causative pathogen in 35% of patients with acute sinusitis, 13% with AECB, and 44% of those with CAP, ratios similar to those of previous studies. The susceptibility to moxifloxacin of 590 S. pneumoniae strains was an MIC 90 of 0.25 mg/L (range, 0.002-2 mg/L). There was no difference in susceptibility to moxifloxacin of the strains from acute sinusitis, AECB, or CAP. The overall eradication rate with moxifloxacin was 95%, irrespective of the moxifloxacin MICs. In 308 S. pneumoniae isolates, there was reduced sensitivity to penicillin (MIC, у0.12 mg/L) in 27% and resistance (MIC, у2.0 mg/L) in 12%. The values for reduced sensitivity and resistance to amoxicillin were 18% and 2%, respectively. A total of 49 (15%) of 321 S. pneumoniae strains, mainly from patients with AECB, were resistant to clarithromycin. The highest MICs of amoxicillin (у2 mg/ L) were for strains of S. pneumoniae from France, Greece, and Mexico. Similarly, the largest number of highly clarithromycinresistant strains was found in France, where clarithromycin MICs of у128 mg/L were recorded for one-third of the strains. Most (32 [94%] of 34) of the S. pneumoniae strains resistant to penicillin or amoxicillin were successfully treated with moxifloxacin, as also reported by Rubio et al. [57] . All 26 clarithromycin-resistant strains were eradicated by moxifloxacin.
H. influenzae was isolated from 23% of the patients with acute sinusitis, 22% with AECB, and 23% of the patients with CAP [58] . The MIC of moxifloxacin for 497 H. influenzae strains was 0.125 mg/L (range, 0.002-32 mg/L). There was no difference in the sensitivity of the strains isolated from acute sinusitis, AECB, or CAP. The overall eradication rate in moxifloxacin-treated patients was 97%, which was unaffected by MICs. The clinical response (resolution or improvement) was successful in 95%, corresponding with the bacterial eradication rate. Thirteen percent of 183 strains of H. influenzae were resistant to amoxicillin, and 11% were resistant to cefuroxime. A total of 27% of the H. influenzae isolates were resistant to clarithromycin (MIC, у32 mg/L), with strains from CAP or AECB having higher MICs than strains from acute sinusitis. With cefuroxime, 89% of the H. influenzae pathogens were eradicated, with an 89% clinical success rate. For clarithromycin, the bacteriologic eradication rate was 73%, with 91% clinical success. The reason for the additional 18% clinical success may be attributed in part to the immunomodulatory capacity of the macrolides. Seventy-eight (6%) patients with RTIs (of whom 64 had AECB) who were treated with moxifloxacin yielded H. parainfluenzae on culture. Clinical success was recorded in 100% of the patients and bacteriologic success in 99%. The modal moxifloxacin value of the isolated H. parainfluenzae was 0.125 mg/ L (range, 0.002-1 mg/L). All strains of H. parainfluenzae were highly sensitive to moxifloxacin, irrespective of whether or not they produced b-lactamase and were otherwise resistant to blactams.
M. catarrhalis was found in 6% of pretreatment isolates in CAP, 13% in acute sinusitis, and 14% in AECB [59] . The MIC of moxifloxacin for 228 strains isolated before treatment was 0.25 mg/L (range, 0.002-1 mg/L). Overall, there was no difference in the MIC of strains isolated from patients with acute sinusitis, CAP, or AECB. The overall eradication rate in patients with RTIs treated with moxifloxacin was 92%, regardless of MICs. The clinical response of resolution or improvement in 92% of patients corresponded with the eradication rate. Fourteen percent of the M. catarrhalis isolates showed intermediate resistance (MIC, у2 mg/L) to amoxicillin, and 7% were resistant (MIC, у4 mg/L).
These values are low in comparison with recent data reported by the Alexander Project, which found almost all strains of M. catarrhalis (90%-100% in most regions) producing b-lactamase [10, 11] . The majority of S. pneumoniae strains were inhibited by moxifloxacin concentrations of 0.06-0.25 mg/L, irrespective of penicillin or macrolide resistance or sensitivity and independently of the clinical condition or the geographic origin of the patients.
H. influenzae and H. parainfluenzae strains were highly susceptible to moxifloxacin, with an MIC 90 The relationship between microbiologic sensitivity data (MICs) of bacteria isolated in clinical trials of RTI with bacteriologic outcomes after moxifloxacin treatment are shown in table 9. The majority (89%-97%) of the different bacterial strains with MICs of р2 mg/L were successfully eradicated by moxifloxacin, whereas only approximately half of the isolates with MICs of 12 mg/L responded. Hence S. pneumoniae, H. influenzae, H. parainfluenzae, and M. catarrhalis can be considered fully sensitive to moxifloxacin (MIC, р2 mg/L).
The breakpoints for moxifloxacin, as suggested to the European authorities and the US Food and Drug Administration are as follows. For the European dossier, sensitive is р1 mg/L and resistant is у4 mg/L for all species. For the US dossier (National Committee for Clinical Laboratory Standards), nonfastidious aerobic microorganisms, susceptible is р2 mg/L and resistant is у8 mg/L. For H. influenzae and H. parainfluenzae (only with Haemophilus test medium, broth microdilution), р1 mg/L is considered susceptible. For Streptococcus species, including S. pneumoniae, resistant is !1 mg/L and susceptible is 14 mg/L (only broth microdilution, Mueller-Hinton broth, and 2%-5% lysed horse blood).
These breakpoints must be related to the magnitude and duration of serum and respiratory tissue concentrations (table  4) . The high serum levels and tissue concentrations, combined with a terminal half-life of 12 h, contribute to attaining and maintaining target tissue concentrations of moxifloxacin well above the MIC 90 for the main respiratory pathogens and thereby provide excellent clinical outcomes for patients with RTIs.
CONCLUSIONS
The excellent in vitro activity of moxifloxacin against respiratory tract pathogens has been confirmed in clinical studies in patients with CAP (5 studies), AECB (4 studies), and acute sinusitis (4 studies). Overall, 94% of the patients treated with moxifloxacin (400 mg once daily) were cured or showed clinical improvement and 95% of bacterial pathogens were eradicated. Moxifloxacin was active against all the common strains of gram-positive, gram-negative, and atypical organisms causing RTIs. Moxifloxacin is also active against strains of S. pneumoniae that are resistant to penicillin or clarithromycin. The correlation between bacterial susceptibility to moxifloxacin and bacteriologic as well as clinical outcome is good.
The studies have shown that moxifloxacin is effective therapy for RTIs caused by S. pneumoniae, H. influenzae, H. parainfluenzae, M. catarrhalis, K. pneumoniae, C. pneumoniae, and M. pneumoniae. The properties of moxifloxacin match those of an antibiotic ideally suited for treating RTIs, and moxifloxacin may therefore be considered for empiric therapy of these common community-acquired bacterial infections.
Moxifloxacin has a number of features that make it appropriate as an empiric treatment for community-acquired RTIs. It demonstrates effective and rapid bactericidal action against both common and less frequent gram-positive, gram-negative, and anaerobic pathogens, as well as atypical respiratory tract pathogens. Additionally, excellent pharmacodynamic and pharmacokinetic properties enable high concentrations to be achieved at key sites of infection. Convenient once-daily dosing is associated with low levels of acquired bacterial resistance. Moxifloxacin has an excellent safety profile, showing few interactions with other drugs and few side effects (especially absence of phototoxicity or hepatic or CNS effects; table 2) and has excellent tolerability. The combination of these properties provides the basis for confident empiric prescribing of moxifloxacin for bacterial RTIs.
